Iron is required for key cellular functions, and there is a strong link between iron metabolism and important metabolic processes, such as cell growth, apoptosis and inflammation. Diseases that are directly or indirectly related to iron metabolism represent major health problems. Iron-regulatory proteins (IRPs) 1 and 2 are key controllers of vertebrate iron metabolism and posttranscriptionally regulate expression of the major iron homeostasis genes. Here we discuss how dysregulation of the IRP system can result from both iron-related and unrelated effectors and explain how this can have important pathological consequences in several human disorders.
Iron is essential for life but can also catalyse the formation of reactive oxygen species (ROS) that can lead to cell damage. Therefore, iron must be safely bound by specialised proteins to keep 'free' iron levels as low as possible. To achieve this, the control of genes encoding proteins involved in iron uptake, utilisation, storage and export must be tightly coordinated. This challenging task is mainly performed by the iron-regulatory proteins (IRPs), which control intracellular iron metabolism, and hepcidin, which regulates body iron homeostasis (Ref. 1). Detailed reviews of IRP structure and regulation have recently been published elsewhere (Refs 2, 3, 4, 5, 6, 7, 8) ; here, we focus on the role of IRPs in maintaining intracellular iron homeostasis and the pathophysiological implications caused by alterations in this function.
The cloning of genes encoding the H and L subunits of the iron-storage protein ferritin led to the identification of iron-responsive elements (IREs) in the 5 0 untranslated regions (UTRs). IREs were found to control gene expression in response to changes in the iron level (Refs 9, 10). Cytosolic proteins that specifically recognise and bind IREs (IRP1 and IRP2) were later identified (Refs 11, 12) , and subsequently the identification of five IRE motifs in the 3 0 UTR of the mRNA for transferrin receptor 1 (TfR1) (approved gene symbol TFRC) (Ref. 13) , which controls cellular iron uptake, indicated that IRPs might be the common regulators of genes involved in iron homeostasis. Indeed, several genes of iron metabolism are now known to be controlled post-transcriptionally through the IRE-IRP regulatory network (see below).
Soon after its identification, it was recognised that IRP1 (approved gene symbol ACO1) is a 'moonlighting' protein that can perform two entirely different functions: when present as an apoform, it is able to bind IRE and control gene expression; however, IRP1 can also assemble a [4Fe-4S] cluster and become the cytosolic counterpart of mitochondrial aconitase. The switch between the two forms is mainly regulated by the availability of iron in the so-called labile iron pool (LIP), a pool of metabolically available iron whose nature is difficult to characterise, but whose importance is widely recognised (Ref. 14) . Therefore, this characteristic makes IRP1 both a sensor of iron levels within the cell and a regulator of cellular iron homeostasis (reviewed by Refs 2, 3, 4, 5, 6, 7, 8) .
Two bands were evident in the first published example of an IRP -IRE bandshift assay (Ref. 11) , and cloning of the human cDNA led to the discovery of the second IRP, which was very similar to IRP1 (Ref. 15) . However, the role of IRP2 (approved gene symbol IREB2) was somewhat neglected until it was demonstrated that it regulates cellular iron homeostasis (Ref. 16 ) and is itself regulated by specific pathophysiological stimuli (Ref. 4 ).
Cellular iron metabolism
The fine adjustment of intracellular iron levels is mainly achieved by means of a divergent but coordinated regulation of the iron-storage protein ferritin and the iron-uptake protein TfR1. Although transcriptional regulation of the ferritin heavy and light subunits (H-ferritin and L-ferritin, respectively) (see Refs 4, 17 for reviews) and of the TFRC gene (Refs 18, 19) in response to iron has been described, these two proteins are mainly controlled at the posttranscriptional level through the IRE-IRP system. Over the past decade it has been shown that other genes involved in iron uptake, release and utilisation are also controlled by the IRE -IRP regulatory network (see below).
IRP1 and IRP2 are cytoplasmic proteins belonging to the aconitase superfamily and regulate intracellular iron metabolism by binding with high affinity and specificity to conserved IREs in the UTRs of mRNA ( Fig. 1 ) (Refs 2, 3, 4, 5, 6, 7, 8) . In spite of the predominantly cytosolic localisation of IRPs, microscopic and biochemical approaches identified a fraction (10%) of IRP1 (but not IRP2) that is associated in a phosphorylationdependent manner with Golgi and endoplasmic reticulum membranes, although the role of membrane-bound IRP1 is still undefined (Ref. 20) . Under conditions of iron deficiency, IRPs actively bind to IREs and stabilise TfR1 mRNA while also decreasing translation of ferritin mRNA, eventually increasing the uptake and availability of iron within the cell. Conversely, high iron levels decrease IREbinding activity, leading to efficient translation of ferritin mRNA and decreased stability of TfR1 mRNA, favouring iron sequestration over uptake (Fig. 1) .
IRP1 is the cytoplasmic counterpart of mitochondrial aconitase, the enzyme that converts citrate to isocitrate through a cisaconitate intermediate in the tricarboxylic acid cycle by means of a catalytic [4Fe-4S] cluster (Ref. 21) . In iron-replete cells the cluster is assembled and IRP1 displays aconitase activity; in iron-depleted cells, no cluster is formed and apo-IRP1 functions as an RNA-binding protein (Fig. 2) . IRE binding is also controlled by the redox state of cysteine residues involved in cluster coordination (Refs 22, 23) . Therefore, it has been proposed that a reversible switch between a cluster-containing holoprotein and a cluster-deficient apoprotein allows aconitase/ IRP1 to constantly sense iron levels and to adapt them to cell requirements without changes in protein levels. However, apo-IRP1 is also subject to iron-dependent degradation (Refs 24, 25) (Fig. 2) , and crystallographic studies did not predict the direct insertion of the cluster in the apo-IRP1 bound to mRNA (Ref. 26) . Therefore, the idea that a single molecule can reversibly assume both forms perhaps needs to be revised; IRP1 exists predominantly in an aconitase form (Refs 27, 28, 29) and de novo formation of either IRP1 or aconitase can be stimulated, depending on iron scarcity or availability, respectively.
In response to increased iron levels, apo-IRP1 is more likely to be degraded than to assemble a [4Fe-4S] cluster, whereas the loss of all four iron atoms that convert cytoplasmic aconitase to the RNA-binding form can probably occur only in response to oxidative or nitrative stress (see below). In addition, it has been shown that protein-kinase-C-dependent phosphorylation controls both the RNA-binding and aconitase activities of IRP1 and influences the mechanisms of IRP1 regulation in response to iron (reviewed by Ref. 7) (Fig. 2) .
IRP2 is highly homologous to IRP1 but lacks aconitase activity, probably because of its inability to assemble a [4Fe-4S] cluster. The protein accumulates in iron-deficient cells and is rapidly targeted for proteasomal degradation in iron-replete cells (Ref. 30) (Fig. 2) . IRP2 binds consensus IRE sequences with an affinity and specificity similar to that of IRP1 (Refs 2, 5), but it has been shown to recognise an exclusive subset of IRE-like motifs (Refs 31, 32 were able to induce reversible inactivation of IRP1 (Refs 35, 67, 68, 69, 70 ). This body of evidence has led to the conclusion that IRP1 downregulation, aimed at decreasing TfR1 levels while also increasing ferritin levels and hence diminishing the LIP, may be a common response to prevent enhanced formation of ROS (Fig. 2) . In line with this, increased ferritin synthesis has been documented in a variety of cell types exposed to oxidative stimuli (Refs 4, 17, 38), whereas reduced oxidative damage has been observed in cells overexpressing H-ferritin (Refs 71, 72, 73). IRP2 is an additional target of ROS produced under conditions of oxidative stress. Available data suggest that IRP2 is highly sensitive to ROS-induced downregulation; this may be triggered by oxidative modifications of sensitive residues and could lead to ubiquitin-dependent proteasomal digestion (Ref. 30) (Fig. 2) . Thus, IRP2 promptly undergoes inactivation in rat liver exposed to glutathione depletion or ischaemia -reperfusion (Refs 35, 68), as well as in cells exposed to menadione (Ref. 70 ). IRP2 is not downregulated in cells exposed to exogenous H 2 O 2 (Refs 2, 3, 4, 38), confirming that extracellular H 2 O 2 acts through mechanisms independently of oxidative stress.
On balance, there is solid evidence to conclude that both IRP1 and IRP2 serve as controllable targets of intracellularly produced ROS. This provides the cell with a regulatory loop to reduce the LIP and prevent further oxidative damage.
IRPs may also be direct or indirect targets of RNIs (Fig. 2) (Fig. 2) . According to another study (Ref. 84) , the formation of the null protein is independent of the action of DOXol on the cluster and derives from the attack of anthracycline -iron complexes on aconitase/IRP1. IRP2 is not attacked by DOXol; only ROS seem to be active in this setting, triggering its degradation (Refs 36, 37).
What are the pathological consequences of the actions of DOXol and ROS on IRP1 and IRP2? The decline of IRP2 that occurs in response to ROS formation might serve as a protective stratagem to facilitate the translation of ferritin mRNA, and to sequester free iron before it converts O 2
Á2
and H 2 O 2 into more-potent oxidants. In fact, DOX treatment increases L-ferritin and H-ferritin synthesis in H9c2 cardiomyocytes (Ref. 37 ) and in mouse hearts (Ref. 85) , with a prominent upregulation of H-ferritin, which has been proposed to have an antioxidant function (Refs 17, 86). IRP1 deficiency does not alter DOX-induced iron metabolism changes nor DOX-induced oxidative damage of the myocardium, showing that high cardiac IRP1 activity in DOX-treated animals does not counteract the potential cardio-protective effect of IRP2 downmodulation (Ref. 85) . However, the conversion of aconitase/IRP1 into a null protein, by making cells unable to sense iron levels, may have a major role in inducing chronic cardiomyopathy, which coincides with the gradual conversion of DOX to DOXol.
The ability of DOX to modulate the RNAbinding activity of both IRP1 and IRP2, and hence the expression of IRE target genes, could be involved in both the antitumour and cardiotoxic properties of the drug, and has produced some important clinical results. Indeed, it has been shown that combining DOX with other antineoplastic drugs (e.g. taxanes) enhances chronic cardiotoxicity because conversion of DOX to DOXol is accelerated (Ref. 82) . Conversely, anthracyclines with a lower level of formation of their alcohol metabolites exhibit reduced cardiotoxicity in expert reviews http://www.expertreviews.org/ in molecular medicine IRPs are also regulated by oxygen tension (reviewed and discussed in Refs 3, 8) , which differentially regulates the binding activity of the two IRPs, with a decrease of IRP1, accompanied by a rise in aconitase activity, and an increase of IRP2 at low oxygen concentrations. Why IRP1 and IRP2 respond in opposite ways to hypoxia remains to be established, but it should be kept in mind that at physiological oxygen tension (3 -5%) IRP2 is the predominant RNA-binding protein, thus possibly explaining its major role in the regulation of iron metabolism (Fig. 2) .
Clinical applications
Hyperferritinaemia with autosomal dominant congenital cataract -a disorder of iron metabolism characterised by early-onset, bilateral nuclear cataracts and elevated serum ferritin concentrations -is the bestcharacterised human disease involving the IRE-IRP regulatory system (reviewed by Refs 88, 89) . In patients affected by this disorder, serum iron and transferrin saturation are normal or low, and body iron (as evaluated by phlebotomy), is not increased, thus excluding iron overload as the underlying cause of hyperferritinaemia. Molecular studies of tissues from these patients have identified multiple point mutations in the IRE of L-ferritin mRNA, which affects the highly conserved CAGUGU motif in the IRE loop responsible for the high-affinity interaction with IRPs (reviewed by Refs 88, 89) . In cultured lymphoblastoid cells from affected patients, the mutation was found to abolish the binding of IRPs and results in constitutively high L-ferritin synthesis, which correlates with serum ferritin levels (Ref. 90) . The affected subjects show no haematological or biochemical abnormalities and the phenotype of this mutation is characterised only by an accumulation of L-ferritin in the lens, resulting in cataract, although a direct relationship between the mutation and the lens deposit of aggregated and crystallised ferritin has not been formally demonstrated.
A point mutation in the IRE of the human H-ferritin gene (approved gene symbol FTH1) has been found in members of a Japanese family affected by iron overload (Ref. 91) 
Mouse models
The role of IRPs in mammalian iron metabolism has been thoroughly studied in cell culture, but relatively little in vivo information is available.
Further information regarding their tissuespecific regulation could be gained by the characterisation of knockout mice bearing conditionally targeted IRP1 and IRP2 loci generated by tissue-specific promoters used to control the cre recombinase (Ref. 
New targets
One main area for future research is expected to be the search for new IRP targets. Integration of bioinformatic, biochemical and genomic approaches has recently led to the identification of new IRP-regulated genes involved in a number of pathways; implementation of these strategies will help in the identification of other IRE-regulated genes and lead to a wider understanding of iron-regulatory networks.
Conclusion
In recent years, the regulation of iron homeostasis has revealed its increasing complexity and its multifaceted and unforeseen interactions with a number of molecular pathways and processes. The work highlighted here has shown that significant advances have been made in elucidating the role of the IRE-IRP network in the post-transcriptional control of key mRNA molecules involved in iron metabolism, but also indicates that further studies are warranted. In particular, we need to gain further insight into the IRP-mediated metabolic remodelling that occurs in response to changes in iron availability and other iron-independent effectors. This information might shed light on the role of iron in the molecular pathophysiology of a wide range of disorders.
